|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 38341 |
FusionGeneSummary for TMEFF2_TMPRSS2 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: TMEFF2_TMPRSS2 | Fusion gene ID: 38341 | Hgene | Tgene | Gene symbol | TMEFF2 | TMPRSS2 | Gene ID | 23671 | 7113 |
| Gene name | transmembrane protein with EGF like and two follistatin like domains 2 | transmembrane serine protease 2 | |
| Synonyms | CT120.2|HPP1|TENB2|TPEF|TR|TR-2 | PP9284|PRSS10 | |
| Cytomap | 2q32.3 | 21q22.3 | |
| Type of gene | protein-coding | protein-coding | |
| Description | tomoregulin-2cancer/testis antigen family 120, member 2hyperplastic polyposis protein 1transmembrane protein TENB2transmembrane protein with EGF-like and two follistatin-like domains | transmembrane protease serine 2epitheliasinserine protease 10transmembrane protease, serine 2 | |
| Modification date | 20180519 | 20180523 | |
| UniProtAcc | Q9UIK5 | O15393 | |
| Ensembl transtripts involved in fusion gene | ENST00000392314, ENST00000272771, ENST00000487771, ENST00000409056, | ENST00000332149, ENST00000398585, ENST00000458356, ENST00000497881, | |
| Fusion gene scores | * DoF score | 7 X 4 X 2=56 | 16 X 12 X 3=576 |
| # samples | 8 | 20 | |
| ** MAII score | log2(8/56*10)=0.514573172829758 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | log2(20/576*10)=-1.52606881166759 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: TMEFF2 [Title/Abstract] AND TMPRSS2 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | Tumor suppressor gene involved fusion gene, in-frame but not retained their domain. Tumor suppressor gene involved fusion gene, retained protein feature but frameshift. DDR (DNA damage repair) gene involved fusion gene, in-frame but not retained their domain. Tissue-specifically expressed gene involved fusion gene, inframe and retained their domain. | ||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | TMEFF2 | GO:0030336 | negative regulation of cell migration | 24632071 |
| Hgene | TMEFF2 | GO:0044319 | wound healing, spreading of cells | 24632071 |
| Hgene | TMEFF2 | GO:0051497 | negative regulation of stress fiber assembly | 24632071 |
| Tgene | TMPRSS2 | GO:0006508 | proteolysis | 21068237|24227843 |
| Tgene | TMPRSS2 | GO:0046598 | positive regulation of viral entry into host cell | 21068237|24227843 |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| TCGA | LD | PRAD | TCGA-KK-A59Y-01A | TMEFF2 | chr2 | 193049080 | - | TMPRSS2 | chr21 | 42851209 | - |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| Frame-shift | ENST00000392314 | ENST00000332149 | TMEFF2 | chr2 | 193049080 | - | TMPRSS2 | chr21 | 42851209 | - |
| Frame-shift | ENST00000392314 | ENST00000398585 | TMEFF2 | chr2 | 193049080 | - | TMPRSS2 | chr21 | 42851209 | - |
| Frame-shift | ENST00000392314 | ENST00000458356 | TMEFF2 | chr2 | 193049080 | - | TMPRSS2 | chr21 | 42851209 | - |
| 5CDS-intron | ENST00000392314 | ENST00000497881 | TMEFF2 | chr2 | 193049080 | - | TMPRSS2 | chr21 | 42851209 | - |
| Frame-shift | ENST00000272771 | ENST00000332149 | TMEFF2 | chr2 | 193049080 | - | TMPRSS2 | chr21 | 42851209 | - |
| Frame-shift | ENST00000272771 | ENST00000398585 | TMEFF2 | chr2 | 193049080 | - | TMPRSS2 | chr21 | 42851209 | - |
| Frame-shift | ENST00000272771 | ENST00000458356 | TMEFF2 | chr2 | 193049080 | - | TMPRSS2 | chr21 | 42851209 | - |
| 5CDS-intron | ENST00000272771 | ENST00000497881 | TMEFF2 | chr2 | 193049080 | - | TMPRSS2 | chr21 | 42851209 | - |
| intron-3CDS | ENST00000487771 | ENST00000332149 | TMEFF2 | chr2 | 193049080 | - | TMPRSS2 | chr21 | 42851209 | - |
| intron-3CDS | ENST00000487771 | ENST00000398585 | TMEFF2 | chr2 | 193049080 | - | TMPRSS2 | chr21 | 42851209 | - |
| intron-3CDS | ENST00000487771 | ENST00000458356 | TMEFF2 | chr2 | 193049080 | - | TMPRSS2 | chr21 | 42851209 | - |
| intron-intron | ENST00000487771 | ENST00000497881 | TMEFF2 | chr2 | 193049080 | - | TMPRSS2 | chr21 | 42851209 | - |
| Frame-shift | ENST00000409056 | ENST00000332149 | TMEFF2 | chr2 | 193049080 | - | TMPRSS2 | chr21 | 42851209 | - |
| Frame-shift | ENST00000409056 | ENST00000398585 | TMEFF2 | chr2 | 193049080 | - | TMPRSS2 | chr21 | 42851209 | - |
| Frame-shift | ENST00000409056 | ENST00000458356 | TMEFF2 | chr2 | 193049080 | - | TMPRSS2 | chr21 | 42851209 | - |
| 5CDS-intron | ENST00000409056 | ENST00000497881 | TMEFF2 | chr2 | 193049080 | - | TMPRSS2 | chr21 | 42851209 | - |
Top |
FusionProtFeatures for TMEFF2_TMPRSS2 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| TMEFF2 | TMPRSS2 |
| Serine protease that proteolytically cleaves andactivates the viral spike glycoproteins which facilitate virus-cell membrane fusions; spike proteins are synthesized andmaintained in precursor intermediate folding states andproteolysis permits the refolding and energy release required tocreate stable virus-cell linkages and membrane coalescence.Facilitates human SARS coronavirus (SARS-CoV) infection via twoindependent mechanisms, proteolytic cleavage of ACE2, which mightpromote viral uptake, and cleavage of coronavirus spikeglycoprotein which activates the glycoprotein for cathepsin L-independent host cell entry. Proteolytically cleaves and activatesthe spike glycoproteins of human coronavirus 229E (HCoV-229E) andhuman coronavirus EMC (HCoV-EMC) and the fusion glycoproteins F0of Sendai virus (SeV), human metapneumovirus (HMPV), humanparainfluenza 1, 2, 3, 4a and 4b viruses (HPIV). Essential forspread and pathogenesis of influenza A virus (strains H1N1, H3N2and H7N9); involved in proteolytic cleavage and activation ofhemagglutinin (HA) protein which is essential for viralinfectivity. {ECO:0000269|PubMed:21068237,ECO:0000269|PubMed:21325420, ECO:0000269|PubMed:23536651,ECO:0000269|PubMed:23966399, ECO:0000269|PubMed:24027332,ECO:0000269|PubMed:24227843}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for TMEFF2_TMPRSS2 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| * Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for TMEFF2_TMPRSS2 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| TMEFF2 | AGO2 | TMPRSS2 | CLK1 |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for TMEFF2_TMPRSS2 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
RelatedDiseases for TMEFF2_TMPRSS2 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | TMEFF2 | C0032460 | Polycystic Ovary Syndrome | 1 | CTD_human |
| Hgene | TMEFF2 | C0033578 | Prostatic Neoplasms | 1 | CTD_human |
| Tgene | TMPRSS2 | C0033578 | Prostatic Neoplasms | 2 | CTD_human |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|